Merck Guides FY26 Below Estimates - Update

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Ana ...